Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation

P. B. Corr, M. H. Creer, K. A. Yamada, J. E. Saffitz, B. E. Sobel

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

Hypoxia in isolated myocytes results in accumulation of long-chain acylcarnitines (LCA) in sarcolemma. Inhibition of carnitine acyltransferase I (CAT-I) with sodium 2-[5-(4-chlorophenyl)-pentyl]-oxirane-2-carboxylate (POCA) prevents both the accumulation of LCA in the sarcolemma and the initial electrophysiologic derangements associated with hypoxia. Another amphiphilic metabolite, lysophosphatidylcholine (LPC), accumulates in the ischemic heart in vivo, in part because of inhibition of its catabolism by accumulating LCA. It induces electrophysiologic alterations in vitro analogous to early changes induced by ischemia in vivo. The present study was performed to determine whether POCA could prevent accumulation of both LCA and LPC induced by ischemia in vivo and if so, whether attenuation of early arrhythmogenesis would result. LAD coronary artery occlusions were induced for 5 min in chloralose-anesthetized cats. Coronary occlusion in untreated control animals elicited prompt, threefold increases of LCA (73 ± 8 to 286 ± 60 pmol/mg protein) and twofold increase of LPC (3.3 ± 0.4 to 7.5 ± 0.9 nmol/mg protein) selectively in the ischemic zone, associated with ventricular tachycardia (VT) or ventricular fibrillation (VF) occurring within the 5-min interval before acquisition of myocardial samples in 64% of the animals. POCA prevented the increase of both LCA and LPC. It also prevented the early occurrence of VT or VF (within 5 min of occlusion) in all animals studied. The antiarrhythmic effect of POCA was not attributable to favorable hemodynamic changes or to changes in myocardial perfusion measured with radiolabeled microspheres. Thus, inhibition of CAT-I effectively reduced the incidence of lethal arrhythmias induced early after the onset of ischemia. Accordingly, pharmacologic inhibition of this enzyme provides a promising approach for prophylaxis of sudden cardiac death, that typically occurs very soon after the onset of acute ischemia, in man.

Original languageEnglish (US)
Pages (from-to)927-936
Number of pages10
JournalJournal of Clinical Investigation
Volume83
Issue number3
DOIs
StatePublished - Jan 1 1989

Fingerprint

Ventricular Fibrillation
Lysophosphatidylcholines
Ethylene Oxide
Ischemia
Carnitine O-Palmitoyltransferase
Sarcolemma
Coronary Occlusion
Ventricular Tachycardia
Chloralose
Sudden Cardiac Death
Microspheres
Muscle Cells
acylcarnitine
Cardiac Arrhythmias
Coronary Vessels
Proteins
Cats
Perfusion
Hemodynamics
Incidence

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Corr, P. B. ; Creer, M. H. ; Yamada, K. A. ; Saffitz, J. E. ; Sobel, B. E. / Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. In: Journal of Clinical Investigation. 1989 ; Vol. 83, No. 3. pp. 927-936.
@article{eada1285fe764634af70fa158568c9ec,
title = "Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation",
abstract = "Hypoxia in isolated myocytes results in accumulation of long-chain acylcarnitines (LCA) in sarcolemma. Inhibition of carnitine acyltransferase I (CAT-I) with sodium 2-[5-(4-chlorophenyl)-pentyl]-oxirane-2-carboxylate (POCA) prevents both the accumulation of LCA in the sarcolemma and the initial electrophysiologic derangements associated with hypoxia. Another amphiphilic metabolite, lysophosphatidylcholine (LPC), accumulates in the ischemic heart in vivo, in part because of inhibition of its catabolism by accumulating LCA. It induces electrophysiologic alterations in vitro analogous to early changes induced by ischemia in vivo. The present study was performed to determine whether POCA could prevent accumulation of both LCA and LPC induced by ischemia in vivo and if so, whether attenuation of early arrhythmogenesis would result. LAD coronary artery occlusions were induced for 5 min in chloralose-anesthetized cats. Coronary occlusion in untreated control animals elicited prompt, threefold increases of LCA (73 ± 8 to 286 ± 60 pmol/mg protein) and twofold increase of LPC (3.3 ± 0.4 to 7.5 ± 0.9 nmol/mg protein) selectively in the ischemic zone, associated with ventricular tachycardia (VT) or ventricular fibrillation (VF) occurring within the 5-min interval before acquisition of myocardial samples in 64{\%} of the animals. POCA prevented the increase of both LCA and LPC. It also prevented the early occurrence of VT or VF (within 5 min of occlusion) in all animals studied. The antiarrhythmic effect of POCA was not attributable to favorable hemodynamic changes or to changes in myocardial perfusion measured with radiolabeled microspheres. Thus, inhibition of CAT-I effectively reduced the incidence of lethal arrhythmias induced early after the onset of ischemia. Accordingly, pharmacologic inhibition of this enzyme provides a promising approach for prophylaxis of sudden cardiac death, that typically occurs very soon after the onset of acute ischemia, in man.",
author = "Corr, {P. B.} and Creer, {M. H.} and Yamada, {K. A.} and Saffitz, {J. E.} and Sobel, {B. E.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1172/JCI113978",
language = "English (US)",
volume = "83",
pages = "927--936",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. / Corr, P. B.; Creer, M. H.; Yamada, K. A.; Saffitz, J. E.; Sobel, B. E.

In: Journal of Clinical Investigation, Vol. 83, No. 3, 01.01.1989, p. 927-936.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation

AU - Corr, P. B.

AU - Creer, M. H.

AU - Yamada, K. A.

AU - Saffitz, J. E.

AU - Sobel, B. E.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Hypoxia in isolated myocytes results in accumulation of long-chain acylcarnitines (LCA) in sarcolemma. Inhibition of carnitine acyltransferase I (CAT-I) with sodium 2-[5-(4-chlorophenyl)-pentyl]-oxirane-2-carboxylate (POCA) prevents both the accumulation of LCA in the sarcolemma and the initial electrophysiologic derangements associated with hypoxia. Another amphiphilic metabolite, lysophosphatidylcholine (LPC), accumulates in the ischemic heart in vivo, in part because of inhibition of its catabolism by accumulating LCA. It induces electrophysiologic alterations in vitro analogous to early changes induced by ischemia in vivo. The present study was performed to determine whether POCA could prevent accumulation of both LCA and LPC induced by ischemia in vivo and if so, whether attenuation of early arrhythmogenesis would result. LAD coronary artery occlusions were induced for 5 min in chloralose-anesthetized cats. Coronary occlusion in untreated control animals elicited prompt, threefold increases of LCA (73 ± 8 to 286 ± 60 pmol/mg protein) and twofold increase of LPC (3.3 ± 0.4 to 7.5 ± 0.9 nmol/mg protein) selectively in the ischemic zone, associated with ventricular tachycardia (VT) or ventricular fibrillation (VF) occurring within the 5-min interval before acquisition of myocardial samples in 64% of the animals. POCA prevented the increase of both LCA and LPC. It also prevented the early occurrence of VT or VF (within 5 min of occlusion) in all animals studied. The antiarrhythmic effect of POCA was not attributable to favorable hemodynamic changes or to changes in myocardial perfusion measured with radiolabeled microspheres. Thus, inhibition of CAT-I effectively reduced the incidence of lethal arrhythmias induced early after the onset of ischemia. Accordingly, pharmacologic inhibition of this enzyme provides a promising approach for prophylaxis of sudden cardiac death, that typically occurs very soon after the onset of acute ischemia, in man.

AB - Hypoxia in isolated myocytes results in accumulation of long-chain acylcarnitines (LCA) in sarcolemma. Inhibition of carnitine acyltransferase I (CAT-I) with sodium 2-[5-(4-chlorophenyl)-pentyl]-oxirane-2-carboxylate (POCA) prevents both the accumulation of LCA in the sarcolemma and the initial electrophysiologic derangements associated with hypoxia. Another amphiphilic metabolite, lysophosphatidylcholine (LPC), accumulates in the ischemic heart in vivo, in part because of inhibition of its catabolism by accumulating LCA. It induces electrophysiologic alterations in vitro analogous to early changes induced by ischemia in vivo. The present study was performed to determine whether POCA could prevent accumulation of both LCA and LPC induced by ischemia in vivo and if so, whether attenuation of early arrhythmogenesis would result. LAD coronary artery occlusions were induced for 5 min in chloralose-anesthetized cats. Coronary occlusion in untreated control animals elicited prompt, threefold increases of LCA (73 ± 8 to 286 ± 60 pmol/mg protein) and twofold increase of LPC (3.3 ± 0.4 to 7.5 ± 0.9 nmol/mg protein) selectively in the ischemic zone, associated with ventricular tachycardia (VT) or ventricular fibrillation (VF) occurring within the 5-min interval before acquisition of myocardial samples in 64% of the animals. POCA prevented the increase of both LCA and LPC. It also prevented the early occurrence of VT or VF (within 5 min of occlusion) in all animals studied. The antiarrhythmic effect of POCA was not attributable to favorable hemodynamic changes or to changes in myocardial perfusion measured with radiolabeled microspheres. Thus, inhibition of CAT-I effectively reduced the incidence of lethal arrhythmias induced early after the onset of ischemia. Accordingly, pharmacologic inhibition of this enzyme provides a promising approach for prophylaxis of sudden cardiac death, that typically occurs very soon after the onset of acute ischemia, in man.

UR - http://www.scopus.com/inward/record.url?scp=0024551414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024551414&partnerID=8YFLogxK

U2 - 10.1172/JCI113978

DO - 10.1172/JCI113978

M3 - Article

C2 - 2921326

AN - SCOPUS:0024551414

VL - 83

SP - 927

EP - 936

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -